Trials / Recruiting
RecruitingNCT06712472
Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 554 (estimated)
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The RAINBO program is a studies group which proposes personalized treatment of patients suffering from endometrial cancer according to their molecular profile. the RAINBO-RED study allows observation or maintenance treatment with targeted therapy for one year (olaparib). This after standard therapy. The goal is to improve recurrence-free survival of patients treated with Olaparib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olaparib (300 mg BID) | Olaparib 300mg Bid during one year. |
Timeline
- Start date
- 2024-06-26
- Primary completion
- 2030-06-01
- Completion
- 2031-12-01
- First posted
- 2024-12-02
- Last updated
- 2026-01-20
Locations
15 sites across 1 country: France
Source: ClinicalTrials.gov record NCT06712472. Inclusion in this directory is not an endorsement.